

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

---

**FORM 8-K**

---

**CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(D) OF  
THE SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): **September 22, 2020**

---

**CRYO CELL International, Inc.**

(Exact Name of Registrant as Specified in its Charter)

---

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**000-23386**  
(Commission  
File No.)

**22-3023093**  
(I.R.S. Employer  
Identification No.)

**700 Brooker Creek Boulevard, Oldsmar, Florida**  
(Address of Principal Executive Offices)

**34677**  
(Zip Code)

Registrant's telephone number, including area code: **(813) 749-2100**

**Not Applicable**  
(Former name or former address, if changed since last report)

---

Securities registered pursuant to Section 12(b) of the Act:

| Title of each class                   | Trading Symbol(s) | Name of each exchange<br>on which registered |
|---------------------------------------|-------------------|--|
| <b>Common Stock, \$0.01 par value</b> | <b>CCEL</b>       | <b>OTCQB</b>                                 |

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Section 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (Section 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

---

**Item 5.07      Submission of Matters to a Vote of Security Holders**

On September 22, 2020, the Company held its Annual Meeting of Stockholders. At the Annual Meeting, stockholders considered the election of five directors, the ratification of the Company's independent registered public accountants and the approval of a non-binding advisory resolution regarding the compensation of the Company's named executive officers in its proxy statement for shareholder consideration.

The final result of the stockholder vote was certified on September 22, 2020 and is as follows:

1. To consider for election five individuals to the Company's Board of Directors

Under plurality voting, the five nominees who received the most "FOR" votes were elected as directors. The Company's stockholders elected the Board of Director's five nominees: Harold Berger; David Portnoy; George Gaines; Jonathan Wheeler, M.D., and Brian Sheehy as directors, each for a one-year term, as follows:

Harold Berger

|          |           |
|----------|-----------|
| For      | 1,393,331 |
| Withhold | 1,163,186 |

George Gaines

|          |           |
|----------|-----------|
| For      | 2,238,776 |
| Withhold | 317,721   |

David I. Portnoy

|          |           |
|----------|-----------|
| For      | 1,754,429 |
| Withhold | 802,068   |

Brian Sheehy

|          |           |
|----------|-----------|
| For      | 2,201,639 |
| Withhold | 354,858   |

Jonathan H. Wheeler, M.D.

|          |           |
|----------|-----------|
| For      | 2,246,488 |
| Withhold | 310,009   |

- 
2. The ratification of the appointment of WIPFLI LLC as the Company's independent registered public accounting firm for the fiscal year ending November 30, 2020.

| <u>For</u> | <u>Against</u> | <u>Abstain</u> |
|------------|----------------|----------------|
| 6,619,468  | 61,354         | 18,869         |

3. The approval of the Company's non-binding resolution regarding the compensation of the Company's named executive officers.

| <u>For</u> | <u>Against</u> | <u>Abstain</u> | <u>Broker Non-Vote</u> |
|------------|----------------|----------------|------------------------|
| 1,303,954  | 1,245,545      | 6,998          | 4,143,194              |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

DATE: September 23, 2020

**Cryo-Cell International, Inc.**

By: /s/ David Portnoy  
David Portnoy  
Chairman and Co-Chief Executive Officer